Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
CA 2448103 A1 · Owner: Glaxo Group Limited · Inventors: Dumaitre, Bernard Andre; Gosmini, Romain Luc Marie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (1) and pharmaceutically acceptable salts solvates and , hydrolysable esters thereof: wherein R1 and R2 are independently H or C1-3 alkyl or R1 and R2 which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X1 represents O or S; Each R3, R4, R8 and R9 independently represents H halogen, -CH3 and OCH3; R5 represents H or C1-6 alkyl or R4 and R5 together form a 3-6 membered cycloalkyl ring. X2 represents NH NCH3 or O; One of Y and , Z is N, and the other is O or S; R6 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one more halogen …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 29, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.